Advanced search
Publication Cover
Cancer Investigation Volume 22, 2004 - Issue 6
Submit an article Journal homepage
56
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Phase II Evaluation of 96-Hour Paclitaxel Infusion in Advanced (Recurrent or Metastatic) Squamous Cell Carcinoma of the Head and Neck (E3395): A Trial of the Eastern Cooperative Oncology Group

Corey J. Langer Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, Pennsylvania, 19111, USA
, M.D.,
Yi Li Dana Farber Cancer Institute, Boston, MassachusettsUSA
, Ph.D.,
Timothy Jennings Albany Medical College, Albany, New YorkUSA
, M.D.,
Ronald C. DeConti H. Lee Moffitt Cancer Center, Tampa, FloridaUSA
, M.D.,
Suresh Nair Geisinger Medical Center, Danville, PennsylvaniaUSA
, M.D.,
Roger B. Cohen Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, Pennsylvania, 19111, USA
, M.D. &
Arlene A. Forastiere Johns Hopkins University, Baltimore, MarylandUSA
, M.D. show all
Pages 823-831 | Published online: 23 Nov 2004

References

  • Moring C. C., Squires T. S., Tony T. Cancer statistics. CA Cancer J. Clin. 1992; 42: 19–38
  • Mitchell E. P., Rodriguez C. V. Head and neck, lung, gastrointestinal and pediatric cancers. Cancer Bull. 1988; 40: 86
  • Pfister D. G., Strong E., Harrison L., et al. Larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer. J. Clin. Oncol. 1991; 9: 850–859, [PUBMED], [INFOTRIEVE]
  • The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Engl. J. Med. 1991; 324: 1685–1690
  • Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the head and neck contracts program. Cancer 1987; 60: 301–311
  • Ervin T. J., Clark J. R., Weichselbaum R. R., et al. An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J. Clin. Oncol. 1987; 5: 10–20, [PUBMED], [INFOTRIEVE]
  • Million R. R., Cassisi N. J., Clark J. R. Cancer of the head and neck. Cancer: Principles and Practice of Oncology, V. T. DeVita, S. Hellman, S. A. Rosenberg. Lippincott, Philadelphia, PA 1989; 488–590
  • Glick J. H., Taylor S. G. Integration of chemotherapy into a combined modality treatment plan for head and neck cancer: a review. Int. J. Radiat. Oncol. Biol. Phys. 1981; 7: 229–242, [PUBMED], [INFOTRIEVE], [CSA]
  • Al-Sarraf M. Head and neck cancer: chemotherapy concepts. Semin. Oncol. 1988; 15: 70–85
  • Urba S. G., Forastiere A. A. Systemic therapy of head and neck cancer: most effective agents, areas of promise. Oncology 1989; 3: 79–98, [PUBMED], [INFOTRIEVE]
  • Kies M. S., Levitan N., Hong K. W. Chemotherapy of head and neck cancer. Otolaryngol. Clin. North Am. 1995; 18: 533–541
  • Recondo G., Armand J. P., Tellez-Bernal E., et al. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy. Laryngoscope 1991; 101: 494–501, [PUBMED], [INFOTRIEVE]
  • Forastiere A. A., Metch B., Schuller D. E., et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck. A Southwest Oncology Group Study. J. Clin. Oncol. 1991; 12: 1245–1251
  • Jacobs C., Lyman G., Valez-Garcia E., et al. A Phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 1992; 10: 257–263, [PUBMED], [INFOTRIEVE]
  • Forastiere A. A., Urba S. G. Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin. Oncol. 1995; 22(3 Suppl. 6)24–27, [PUBMED], [INFOTRIEVE]
  • Liebman J. E., Cook J. A., Lipschultz C., et al. Cytotoxic studies of paclitaxel in human tumor cell lines. Br. J. Cancer 1993; 63: 1104–1109
  • Chang A., Boros L., Garrow G., Asbury R. Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Semin. Oncol. 1995; 22(3 Suppl. 6)124–127, [PUBMED], [INFOTRIEVE]
  • Wilson W. H., Berg S. L., Bryant G., et al. Paclitaxel in doxorubicin or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J. Clin. Oncol. 1994; 12: 1621–1625, [PUBMED], [INFOTRIEVE]
  • Seidman A. D., Hochhouser D., Gollub M., et al. Ninety-six hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J. Clin. Oncol. 1994; 14: 1877–1884
  • Hudes G., Nathan F. E., Khater C., et al. Paclitaxil plus estramustine in metastatic hormone-refractory prostate cancer. Semin. Oncol. 1995; 22(suppl. 12)41–45, [PUBMED], [INFOTRIEVE]
  • Georgiadis M. S., Schuller B. S., Brown J. E., et al. Paclitaxil by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer. J. Clin. Oncol. 1997; 15: 735–743, [PUBMED], [INFOTRIEVE]
  • Oken M. M., Creech R. H., Tormey D. C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655, [PUBMED], [INFOTRIEVE]
  • Agresti A. Categorical Data Analysis. Wiley, New York 1990
  • Bahadur RR. Stochastic comparison of tests. Ann. Math. Stat. 1960; 31: 276–295
  • Cox DR. Regression models and life tables. J.R. Stat. Soc. 1972; 34: 187–202
  • Kaplan E. L., Meier P. Nonparametric estimation of incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481, [CSA]
  • Murphy B., Li Y., Cella D., et al. Phase III study comparing cisplatin (C) and 5-Flurouracil (F) vs. cisplatin and paclitaxel (T) in metastatic/recurrent head and neck cancer (MHNC). Proc. Am. Soc. Clin. Oncol. 2001; 20: A-894, (abstract)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.